[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340839-105":3,"doc-detail-340839-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","josephin-domain-containing-protein-2-josd2-promotes-lung-cancer-by-inhibiting-lkb1-liver-kinase-b1-activity","Josephin Domain-containing protein 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity","","Non-small cell lung cancer (NSCLC) causes widespread cancer deaths, yet kinase-targeted therapies benefit only about 30% of patients, highlighting the need for new strategies. Deubiquitinases (DUBs) are frequently overactivated in cancers but how they drive NSCLC remains unclear. Global analysis of 97 DUBs using TCGA shows high JOSD2 expression predicts poor prognosis. JOSD2 depletion blocks NSCLC growth in vivo; JOSD2 suppresses LKB1 kinase activity by removing K6-linked polyubiquitination and supports complex integrity. A first JOSD2 small-molecule inhibitor arrests NSCLC proliferation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/josephin-domain-containing-protein-2-josd2-promotes-lung-cancer-by-inhibiting-lkb1-liver-kinase-b1-activity/340839/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/josephin-domain-containing-protein-2-josd2-promotes-lung-cancer-by-inhibiting-lkb1-liver-kinase-b1-activity/340839.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in NSCLC treatment?","Question",{"text":63,"@type":64},"Kinase-targeted therapies are effective only for a small fraction of NSCLC patients, so new therapeutic strategies are urgently needed.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is JOSD2 linked to NSCLC prognosis and growth?",{"text":68,"@type":64},"High JOSD2 expression correlates with poor patient prognosis, and depleting JOSD2 significantly impedes NSCLC growth in vivo.",{"name":70,"@type":61,"acceptedAnswer":71},"What molecular mechanism connects JOSD2 to LKB1 activity?",{"text":72,"@type":64},"JOSD2 restricts LKB1 kinase activity by removing K6-linked polyubiquitination, which is important for maintaining the integrity of the LKB1-STRAD-MO25 complex.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340839,1790782039,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399",8,"Signal Transduction [and Targeted Therapy](and Targeted Therapy www.nature.com/sigtrans)[ www.nature.com/sigtrans](and Targeted Therapy www.nature.com/sigtrans)  \nJosephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity  \nTao Yuan1, Chenming Zeng2, Jiawei Liu3, Chenxi Zhao1, Fujing Ge1, Yuekang Li1, Meijia Qian 1, Jiamin Du 1, Weihua Wang1, Yonghao Li 1, Yue Liu1, Xiaoyang Dai4, Jianya Zhou5, Xueqin Chen6, Shenglin Ma6, Hong Zhu1,7 ✉, Qiaojun He1,8 ✉ and Bo Yang1 ✉  \n\n| | Non-small cell lung cancer (NSCLC) ranks as one of the leading causes of cancer-related deaths worldwide. Despite the prominence and effectiveness of kinase-target therapies in NSCLC treatment, these drugs are suitable for and beneﬁcial to a mere ~30% of NSCLC patients. Consequently, the need for novel strategies addressing NSCLC remains pressing. Deubiquitinases (DUBs), a group of diverse enzymes with well-deﬁned catalytic sites that are frequently overactivated in cancers and associated with tumorigenesis and regarded as promising therapeutic targets. Nevertheless, the mechanisms by which DUBs promote NSCLC remain poorly understood. Through a global analysis of the 97 DUBs’ contribution to NSCLC survival possibilities using The Cancer Genome Atlas (TCGA) database, we found that high expression of Josephin Domain-containing protein 2 (JOSD2) predicted the poor prognosis of patients. Depletion of JOSD2 signiﬁcantly impeded NSCLC growth in both cell/patient-derived xenografts in vivo. Mechanically, we found that JOSD2 restricts the kinase activity of LKB1, an important tumor suppressor generally inactivated in NSCLC, by removing K6-linked polyubiquitination, an action vital for maintaining the integrity of the LKB1-STRAD-MO25 complex. Notably, we identiﬁed the ﬁrst small-molecule inhibitor of JOSD2, and observed that its pharmacological inhibition signiﬁcantly arrested NSCLC proliferation in vitro/in vivo. Our ﬁndings highlight the vital role of JOSD2 in hindering LKB1 activity, underscoring the therapeutic potential of targeting JOSD2 in NSCLC, especially in those with inactivated LKB1, and presenting its inhibitors as a promising | |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  | |\n|  |  |  |\n| | strategy for NSCLC treatment. | |\n|  | Signal Transduction and Targeted Therapy (2024)9:11 ; [https://doi.org/10.1038/s41392-023-01706-y](https://doi.org/10.1038/s41392-023-01706-y) |  |\n|  |  |  |\n\nINTRODUCTION  \nNon-small cell lung cancer (NSCLC), which accounts for approximately 85% of lung cancer, is one of the leading causes of cancer death worldwide.1 Kinase-targeted therapies such as EGFR, ALKand MET inhibitors are commonly used to treat NSCLC patients.2 However, only ~30% NSCLC patients harbor the activating mutations in these kinases hence are responsive to these therapies.3 Therefore, further understanding of NSCLC tumorigenesis is in urgent need for developing more effective therapeutic treatments.  \nThe deubiquitinases (DUBs), a group of diverse enzymes with well-deﬁned catalytic sites that are frequently overactivated in cancers, have attracted much attention recently as potential therapeutic targets. For instance, OTUD6B, USP7 and COPS5, frequently found overexpressed in breast cancers, have been regarded as promising therapeutic targets.4,5 Nevertheless, the underlying mechanisms of DUBs in promoting NSCLC tumorigenesis remain poorly understood, which has hindered the discovery of DUBs inhibitors for NSCLC treatment. This warrants thorough investigation on identifying DUBs with important oncogenic roles in NSCLC and further elucidate their tumorigenic mechanisms.  \nIn our analysis, Josephin Domain-containing protein 2 (JOSD2) stood out as its high expression was signiﬁcantly correlated with poor prognosis of NSCLC patients and depletion of JOSD2 posed most potent inhibitory effects on NSCLC cell growth. J","cbCaicijsvJ4zIB7","https://ap.wps.com/l/cbCaicijsvJ4zIB7","pdf",7362591,16,"English","# Introduction\n## NSCLC burden and limited kinase-targeted response\n## DUBs as therapeutic targets and knowledge gaps\n## Rationale for investigating JOSD2\n## Role of LKB1 in NSCLC","[{\"question\":\"What problem does the study address in NSCLC treatment?\",\"answer\":\"Kinase-targeted therapies are effective only for a small fraction of NSCLC patients, so new therapeutic strategies are urgently needed.\"},{\"question\":\"How is JOSD2 linked to NSCLC prognosis and growth?\",\"answer\":\"High JOSD2 expression correlates with poor patient prognosis, and depleting JOSD2 significantly impedes NSCLC growth in vivo.\"},{\"question\":\"What molecular mechanism connects JOSD2 to LKB1 activity?\",\"answer\":\"JOSD2 restricts LKB1 kinase activity by removing K6-linked polyubiquitination, which is important for maintaining the integrity of the LKB1-STRAD-MO25 complex.\"}]","Josephin Domain-containing protein 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity | PDF",1790039114,40,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0de61ada8c5da43721fea203c799d0f.webp",983,1305,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e702b85c82357fab8f82cd961b080b0.webp",982,1304,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af3a4d2a4320424a959e0f336cca4daa.webp",981,1303,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc4893e69e4feedfa156f1b2dbdd730e.webp",980,1301,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,144,147,152,155,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":141,"doc_module":4,"doc_module_name":25,"category_name":142,"show_sort_weight":98,"slug":143},7,"Healthcare","healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":145,"slug":146},30,"research-report",{"id":148,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},9,"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":131,"slug":162},19,"General","general"]